title: Pertuzumab to bolster Roche/Genentech's breast cancer franchise?
authors: Cormac
authors: C
authors: Sheridan
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics; D005260:Female; D006801:Humans; D011379:Prognosis; D055503:Protein Multimerization; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D015398:Signal Transduction; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human; C485206:pertuzumab